These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11772695)

  • 21. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
    Kasper S; Volz HP; Möller HJ; Dienel A; Kieser M
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment.
    Romano SJ; Halmi KA; Sarkar NP; Koke SC; Lee JS
    Am J Psychiatry; 2002 Jan; 159(1):96-102. PubMed ID: 11772696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing escitaloipram with sertraline for obsessive and compulsive symptoms in patients with obsessive compulsive disorder: A comparative double blind clinical trial.
    Mowla A; Modarresi F; Dastgheib SA
    Asian J Psychiatr; 2018 Dec; 38():92-95. PubMed ID: 29158148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
    Etain B; Bonnet-Perrin E
    Encephale; 2001; 27(3):280-9. PubMed ID: 11488259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients.
    Rasmussen A; Lunde M; Poulsen DL; Sørensen K; Qvitzau S; Bech P
    Psychosomatics; 2003; 44(3):216-21. PubMed ID: 12724503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
    Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sertraline treatment of panic disorder: results of a long-term study.
    Rapaport MH; Wolkow R; Rubin A; Hackett E; Pollack M; Ota KY
    Acta Psychiatr Scand; 2001 Oct; 104(4):289-98. PubMed ID: 11722304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
    Greist JH; Jefferson JW; Rosenfeld R; Gutzmann LD; March JS; Barklage NE
    J Clin Psychiatry; 1990 Jul; 51(7):292-7. PubMed ID: 2195006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
    McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
    J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is mirtazapine augmentation effective for patients with obsessive-compulsive disorder who failed to respond to sertraline monotherapy? A placebo-controlled, double-blind, clinical trial.
    Mowla A; Baniasadipour H
    Int Clin Psychopharmacol; 2023 Jan; 38(1):4-8. PubMed ID: 35695582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder.
    Koran LM; Bromberg D; Hornfeldt CS; Shepski JC; Wang S; Hollander E
    Compr Psychiatry; 2010; 51(4):373-9. PubMed ID: 20579510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.
    Pigott TA; L'Heureux F; Rubenstein CS; Bernstein SE; Hill JL; Murphy DL
    J Clin Psychopharmacol; 1992 Jun; 12(3):156-62. PubMed ID: 1629380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder.
    Crockett BA; Churchill E; Davidson JR
    Ann Clin Psychiatry; 2004; 16(3):127-32. PubMed ID: 15517844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clomipramine in obsessive-compulsive disorder.
    Katz RJ; DeVeaugh-Geiss J; Landau P
    Biol Psychiatry; 1990 Sep; 28(5):401-14. PubMed ID: 2207219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents.
    March JS; Klee BJ; Kremer CM
    J Child Adolesc Psychopharmacol; 2006; 16(1-2):91-102. PubMed ID: 16553531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan.
    Kamijima K; Burt T; Cohen G; Arano I; Hamasaki T
    Int Clin Psychopharmacol; 2006 Jan; 21(1):1-9. PubMed ID: 16317311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time to relapse after short- or long-term treatment of severe premenstrual syndrome with sertraline.
    Freeman EW; Rickels K; Sammel MD; Lin H; Sondheimer SJ
    Arch Gen Psychiatry; 2009 May; 66(5):537-44. PubMed ID: 19414713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study.
    Pakseresht S; Boostani H; Sayyah M
    J Complement Integr Med; 2011 Oct; 8():. PubMed ID: 22718671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial.
    Sarris J; Byrne G; Castle D; Bousman C; Oliver G; Cribb L; Blair-West S; Brakoulias V; Camfield D; Ee C; Chamoli S; Boschen M; Dean OM; Dowling N; Menon R; Murphy J; Metri NJ; Nguyen TP; Wong A; Jordan R; Karamacoska D; Rossell SL; Berk M; Ng CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jul; 117():110550. PubMed ID: 35304155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome.
    Greiss Hess L; Fitzpatrick SE; Nguyen DV; Chen Y; Gaul KN; Schneider A; Lemons Chitwood K; Eldeeb MA; Polussa J; Hessl D; Rivera S; Hagerman RJ
    J Dev Behav Pediatr; 2016 Oct; 37(8):619-28. PubMed ID: 27560971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.